F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients

by Vandana Singh, Benzinga Editor

August 12, 2021 11:07 AM | 1 min read |

F-star Therapeutics Inc FSTX has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.
The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).
FS118 is a bispecific antibody targeting LAG-3 and PD-L1.
In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.
F-Star ended the quarter with cash and cash equivalents of $81.6 million.
Price Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.

Posted In: Biotech Earnings News Health Care Movers Trading Ideas General Briefs lymphoma Non-Small Cell Lung Cancer

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.